About Cocrystal Pharma (OTCMKTS:COCP)
Cocrystal Pharma, Inc., formerly Biozone Pharmaceuticals, Inc., is engaged in developing medicines for use in the treatment of human viral diseases. The Company develops technologies and approaches to create antiviral drug candidates. The Company is developing antiviral therapeutics that inhibit the replication function of a virus, including the ribonucleic acid (RNA)-dependent RNA polymerase enzyme, the helicase enzyme and the NS5A protein of hepatitis C virus (HCV), and the polymerase enzymes of influenza virus and norovirus. The polymerase inhibitors include both nucleosides (Nucs) and non-nucleosides. Its platform consists of computation, medicinal chemistry, click chemistry and X-ray crystallography. The Company determines the structures of cocrystals containing the inhibitors bound to the enzyme or protein to guide its design. The Company uses computational methods to screen and design product candidates using its cocrystal structural information.
Industry, Sector and Symbol
Industry Drug Related Products
Trailing P/E Ratio-1.945
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-8.97%
Return on Assets-7.35%
Cocrystal Pharma (OTCMKTS:COCP) Frequently Asked Questions
What is Cocrystal Pharma's stock symbol?
Cocrystal Pharma trades on the OTCMKTS under the ticker symbol "COCP."
Who are some of Cocrystal Pharma's key competitors?
Some companies that are related to Cocrystal Pharma include MannKind (MNKD), Arbutus Biopharma (ABUS), Syros Pharmaceuticals (SYRS), Sequenom (SQNM), Bellicum Pharmaceuticals (BLCM), Simulations Plus (SLP), Aquinox Pharmaceuticals (AQXP), Cellular Biomedicine Group (CBMG), Palomar Medical Technologies (PMTI), Trilogy International Partners (TRL), RTI Surgical (RTIX), GTX (GTXI), Cellular Dynamics International (ICEL), Fluidigm (FLDM), Marinus Pharmaceuticals (MRNS), Cannabis Science (CBIS), Minerva Neurosciences (NERV) and Celsius (CELH).
Who are Cocrystal Pharma's key executives?
Cocrystal Pharma's management team includes the folowing people:
- Raymond F. Schinazi Ph.D., Chairman of the Board (Age 65)
- Sam Lee, President (Age 56)
- Gary L. Wilcox Ph.D., Interim Chief Executive Officer, Vice Chairman of the Board (Age 69)
- James J. Martin, Chief Financial Officer (Age 50)
- David S. Block M.D., , Director (Age 56)
- Phillip Frost, Director (Age 79)
- Jane Hsiao Ph.D., M.B.A.,, Director (Age 68)
- Steven Rubin, Director (Age 55)
How do I buy Cocrystal Pharma stock?
Shares of Cocrystal Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cocrystal Pharma's stock price today?
One share of Cocrystal Pharma stock can currently be purchased for approximately $0.19.
How big of a company is Cocrystal Pharma?
Cocrystal Pharma has a market capitalization of $145.65 million.
How can I contact Cocrystal Pharma?
Cocrystal Pharma's mailing address is 1860 Montreal Rd, TUCKER, GA 30084-5709, United States. The company can be reached via phone at +1-425-3987178.
MarketBeat Community Rating for Cocrystal Pharma (COCP)MarketBeat's community ratings are surveys of what our community members think about Cocrystal Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cocrystal Pharma (OTCMKTS:COCP) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Earnings History for Cocrystal Pharma (OTCMKTS:COCP)
No earnings announcements for this company have been tracked by MarketBeat.com
Cocrystal Pharma (OTCMKTS:COCP) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Cocrystal Pharma (OTCMKTS:COCP)
No dividend announcements for this company have been tracked by MarketBeat.com
Cocrystal Pharma (OTCMKTS COCP) Insider Trading and Institutional Ownership History
Cocrystal Pharma (OTCMKTS COCP) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/23/2016||Sam Lee||President||Sell||2,200,000||$0.44||$968,000.00||13,087,847|| |
|9/1/2016||Gary Wilcox||CEO||Buy||10,000||$0.41||$4,100.00|| |
|9/1/2016||Raymond F Schinazi||Director||Buy||4,878,050||$0.41||$2,000,000.50||275,520,853|| |
|3/15/2016||Jane Ph D Hsiao||Director||Buy||1,235,294||$0.51||$629,999.94||3,435,294|| |
|3/15/2016||Jeffrey A Meckler||CEO||Buy||294,118||$0.51||$150,000.18||657,161|| |
|12/23/2015||Jeffrey A Meckler||CEO||Buy||100,000||$0.58||$58,000.00||363,043|| |
|4/21/2015||Raymond F Schinazi||Director||Buy||3,464,855||$0.92||$3,187,666.60|| |
|3/25/2015||Gary Wilcox||CEO||Buy||54,348||$0.92||$50,000.16|| |
|3/25/2015||Jeffrey A Meckler||Director||Buy||163,043||$0.92||$149,999.56|| |
|12/15/2014||Phillip Md Et Al Frost||Director||Buy||25,000||$0.43||$10,750.00|| |
|8/12/2014||Phillip Md Et Al Frost||Director||Buy||111,200||$0.29||$32,248.00|| |
Cocrystal Pharma (OTCMKTS COCP) News Headlines
|Cocrystal Pharma Announces Filing 2017 Third Quarter Financial Statements and Provides Company Update|
finance.yahoo.com - November 8 at 9:40 PM
|Cocrystal Pharma to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference in New York|
finance.yahoo.com - September 22 at 9:46 AM
|Cocrystal Pharma, HitGen and InterX Enter into Drug Discovery Collaboration|
finance.yahoo.com - September 5 at 6:59 PM
|Cocrystal Announces Positive Data from the Successful Completion of Phase 1a/1b Trial of the Non-Nucleoside Polymerase Inhibitor CC-31244 for the Treatment of Chronic Hepatitis C Infection|
finance.yahoo.com - August 15 at 6:07 PM
|PolarityTE: Will This Biotech Be The Next Amazon Or Tesla?|
www.forbes.com - August 8 at 5:07 PM
|Cocrystal Pharma Announces Filing 2017 Second Quarter Financial Statements and Provides Company Update|
finance.yahoo.com - August 8 at 5:07 PM
|MDCO Tastes Bitter, PRTO Awaits Phase 3 Data In Dec., It's Time To Cherish IONS|
www.nasdaq.com - November 8 at 12:56 PM
|COCRYSTAL PHARMA, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders|
biz.yahoo.com - July 29 at 4:18 PM
|COCRYSTAL PHARMA, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 15 at 5:14 PM
|COCRYSTAL PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure|
biz.yahoo.com - February 12 at 5:11 PM
|COCRYSTAL PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibi|
biz.yahoo.com - November 20 at 5:10 PM
|COCRYSTAL PHARMA, INC. Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - November 16 at 4:16 PM
|COCRYSTAL PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - October 2 at 4:07 PM
Cocrystal Pharma (OTCMKTS:COCP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Cocrystal Pharma (OTCMKTS COCP) Stock Chart for Wednesday, January, 17, 2018